Analyst Cautiously Optimistic on ISIS (ISIS) SMN (Rx)
Tweet
Share
E-mailGet Alerts ISIS Hot Sheet
Price: $57.56 --0%
Rating Summary:
7 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Rating Summary:
7 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Join SI Premium – FREE
Leerink Swann today maintained a Market Perform rating on ISIS Pharmaceuticals (NASDAQ: ISIS) and boosted its price target to $18.00 (from $14.00). Analyst Joseph P. Schwartz said he believes that uncontrolled Phase I data for ISIS-SMN presented at the Annual American Academy of Neurology (AAN) meeting contained no surprises.
The raised price target reflects increased in the probability of success for SMN-Rx and TTR-Rx (both advancing to Phase III) to 85% from 33%.
For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.
Shares of ISIS Pharmaceuticals closed at $17.84 yesterday.
The raised price target reflects increased in the probability of success for SMN-Rx and TTR-Rx (both advancing to Phase III) to 85% from 33%.
For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.
Shares of ISIS Pharmaceuticals closed at $17.84 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
- HSBC Upgrades Topdanmark (TOP:DC) (TPDKY) to Hold
- Equifax (EFX) PT Raised to $240 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
